Fatty acid side chain modifications Liraglutide The conjugation of a fatty acid chain to GLP-1 analogs significantly enhances their binding affinity to human serum albumin, thereby generating long-acting peptide formulations with improved pharmacokinetic profiles
To ensure market exclusivity, Novo Nordisk and Eli Lilly have secured patents for these drugs worldwide
GLP-1 therapy works best when paired with professional follow-up, individualized dosing, and a supportive healthcare team
Methods: A narrative review with a structured literature search was conducted using PubMed, Embase, and Cochrane Library databases from inception to March 2025
Supplementary information Supplementary Figures and Tables (PDF 594 kb) PowerPoint slides Rights and permissions About this article Cite this article Muskiet, M., Tonneijck, L., Smits, M
Generic Semaglutide in Canada: 9 Applications Under Review, but the Timeline Is Slipping Health Canada now has 9 generic semaglutide applications under active review from companies including Sandoz, Apotex, Teva, Taro, and Aspen Pharmacare
